Evidence map›Paper›PMID 36824856›Full record

ArticlebioRxiv : the preprint server for biology2023

Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degraders.

Yen-Der Li, Michelle W Ma, Muhammad Murtaza Hassan, Moritz Hunkeler, Mingxing Teng, Kedar Puvar, Ryan Lumpkin, Brittany Sandoval, Cyrus Y Jin, Scott B Ficarro and 18 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 45 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 6 institutions in 1 country.

Yen-Der LiDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA.
Michelle W MaDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA.
Muhammad Murtaza HassanDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford , School of Medicine, Stanford University, Stanford, CA.
Moritz HunkelerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Mingxing TengDepartment of Pathology & Immunology, and Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX.
Kedar PuvarDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Ryan LumpkinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Brittany SandovalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Cyrus Y JinDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Scott B FicarroDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Michelle Y WangDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Shawn XuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Brian J GroendykeDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Logan H SiguaDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Isidoro TavaresDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Charles ZouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jonathan M TsaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Paul M C ParkDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Hojong YoonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Felix C MajewskiDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford , School of Medicine, Stanford University, Stanford, CA.
Jarrod A MartoDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Jun QiDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Radosław P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Katherine A DonovanDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Mikołaj SłabickiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Nathanael S GrayDepartment of Chemical and Systems Biology, Chem-H and Stanford Cancer Institute, Stanford , School of Medicine, Stanford University, Stanford, CA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA.
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Dana-Farber Cancer Institute · USHarvard University · USBroad Institute · USStanford University · USBaylor College of Medicine · USBrigham and Women's Hospital · US

Funding

TYROSINE KINASE ONCOGENESIS IN MYELOID LEUKEMIAP01CA066996 · NCI · DANA-FARBER CANCER INSTITUTE · PI SCOTT A ARMSTRONG · 1996 to 2026
$52.5M
Illuminating Function of the Understudied Druggable KinomeU24DK116204 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOHNSON, GARY L. · 2017 to 2022
$13.6M
Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6M
Functional Genomic Dissection of Refractory AnemiaR01HL082945 · NHLBI · DANA-FARBER CANCER INSTITUTE · PI EBERT, BENJAMIN LEVINE · 2005 to 2022
$6.8M
The role of clonal hematopoiesis in the development and therapy of myeloid malignanciesR35CA253125 · NCI · DANA-FARBER CANCER INST · PI EBERT, BENJAMIN LEVINE · 2020 to 2024
$4.9M
(PQ5) Contribution of mitochondrial pathways to metabolic heterogeneity in molecular subtypes of Diffuse Large B Cell LymphomaR01CA219850 · NCI · DANA-FARBER CANCER INST · PI DANIAL, NIKA N, MARTO, JARROD A. · 2018 to 2022
$2.8M
Novel Screening Platform for Discovery of DUB Targeting ProbesR01CA233800 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2019 to 2022
$2.5M
Development of a generalizable chemo-proteomics screening platform for small molecule degraders applied to HDACsR01CA262188 · NCI · DANA-FARBER CANCER INST · PI FISCHER, ERIC SEBASTIAN · 2022 to 2025
$1.8M
500 MHz NMR Spectrometer System with High Sensitivity Cryoprobe and Automated Sample Changer for Biochemical ResearchS10OD028697 · OD · STANFORD UNIVERSITY · PI BURNS, NOAH ZACHARY · 2020 to 2020
$709k
Tools for DUB Drug DiscoveryR21CA247671 · NCI · DANA-FARBER CANCER INST · PI BUHRLAGE, SARA J, MARTO, JARROD A. · 2020 to 2021
$648k
Expanding pharmacological modalities for targeted cancer therapyK00CA253754 · NCI · BROAD INSTITUTE, INC. · PI YOON, HOJONG · 2021 to 2023
$292k
NCI NIH HHS P01 CA066996NCI NIH HHS P50 CA206963NCI NIH HHS R01 CA219850NCI NIH HHS R01 CA233800NCI NIH HHS R01 CA262188NCI NIH HHS R21 CA247671NCI NIH HHS R35 CA253125NHLBI NIH HHS R01 HL082945NIDDK NIH HHS U24 DK116204NIH HHS S10 OD028697
6 · The paper itself

Abstract

Small molecules that induce protein-protein interactions to exert proximity-driven pharmacology such as targeted protein degradation are a powerful class of therapeutics

Identifiers

PMID36824856
PMCPMC9949066
OpenAlexW4320896409

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.